CytoMed Therapeutics (GDTC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GDTC · Stock Price

USD 0.72-1.50 (-67.43%)

Market Cap: $8.3M

Historical price data

Market Cap: $8.3MPipeline: 3 drugsFounded: 2018HQ: Singapore, Singapore

Sector Ranking#92 in Cell & Gene Therapy #160 in Oncology (General)

Overview

CytoMed Therapeutics is a clinical-stage biotech focused on translating innovative allogeneic cell therapies into treatments for a broad spectrum of cancers. Its mission is to overcome the manufacturing complexity, cost, and delay associated with autologous cell therapies by leveraging donor-derived gamma-delta T cells and NK cells. The company has established a dual-platform strategy, combining its proprietary cell expansion techniques with CAR engineering, and is progressing multiple candidates towards clinical validation. As a public entity, CytoMed is positioned within Singapore's strong biomedical ecosystem to advance its next-generation immunotherapy pipeline.

Oncology

Technology Platform

CytoMed's core technology involves the proprietary expansion and CAR-engineering of donor-derived gamma-delta T cells for allogeneic use, complemented by a developing iPSC platform for generating immune effector cells.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafte...	Cancer	Phase 1
human Mesenchymal Stem Cell (MSC) infusion therapy	Aging Well	Phase 1
Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen...	Colorectal Cancer	Phase 1

Funding History

3

Total raised:$18.5M

IPO$12MUndisclosedFeb 8, 2023

Series A$5MUndisclosedMar 15, 2021

Seed$1.5MUndisclosedJun 15, 2020

Opportunities

CytoMed is positioned in the high-growth allogeneic cell therapy market, targeting the major unmet need in solid tumors.

Its γδ T cell platform offers a differentiated biological approach with potential safety and solid tumor penetration advantages over competing modalities.

Risk Factors

The company faces significant clinical development risk, financial risk as a pre-revenue micro-cap, and intense competition from better-funded rivals in the allogeneic cell therapy space.

Successful translation from promising preclinical data to human efficacy is unproven.

Competitive Landscape

CytoMed competes in the crowded allogeneic cell therapy arena against companies like Allogene and Fate Therapeutics. Its primary differentiation is the focus on γδ T cells, which may offer inherent safety and solid tumor advantages, but it faces competition from other γδ T cell specialists like Adicet Bio.